Cancer Genetics, Inc. (CGIX) financial statements (2021 and earlier)

Company profile

Business Address 201 ROUTE 17 NORTH
RUTHERFORD, NJ 07070
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments24010101926
Cash and cash equivalents24010101926
Restricted cash and investments 0     
Receivables117111275
Inventory, net of allowances, customer advances and progress billings  00000
Inventory  00000
Prepaid expense      1
Disposal group, including discontinued operation 0     
Assets held-for-sale, not part of disposal group0     
Other current assets1123221
Other undisclosed current assets 1(0)(0)(0)(0)(1)
Total current assets:47923232832
Noncurrent Assets
Property, plant and equipment 146564
Long-term investments and receivables0     1
Long-term investments0     1
Intangible assets, net (including goodwill)      3
Goodwill      3
Intangible assets, net (excluding goodwill)      1
Deposits noncurrent assets      0
Restricted cash and investments      6
Other noncurrent assets472223141511
Other undisclosed noncurrent assets0     (11)
Total noncurrent assets:482629192115
TOTAL ASSETS:8153552424947
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:22139884
Accrued liabilities     00
Other undisclosed accounts payable and accrued liabilities22139873
Deferred revenue11
Debt021110210
Derivative instruments and hedges, liabilities  0    
Due to related parties 11    
Disposal group, including discontinued operation11     
Deferred revenue and credits1111
Contract with customer, liability2
Other undisclosed current liabilities000    
Total current liabilities:47272011104
Noncurrent Liabilities
Long-term debt and lease obligation00 1356
Long-term debt, excluding current maturities    356
Finance lease, liability00
Capital lease obligations 1000
Operating lease, liability00
Liabilities, other than long-term debt0015312
Deferred revenue and credits1111
Accounts payable and accrued liabilities  0    
Contract with customer, liability0
Due to related parties 0     
Other liabilities      1
Derivative instruments and hedges, liabilities0004200
Other undisclosed noncurrent liabilities  0    
Total noncurrent liabilities:0116668
Total liabilities:482925171613
Stockholders' equity
Stockholders' equity attributable to parent, including:47727263335
Common stock  00000
Additional paid in capital177172164162140131113
Accumulated other comprehensive income (loss)(0)000   
Accumulated deficit(172)(164)(158)(135)(114)(98)(78)
Warrants and rights outstanding      0
Other undisclosed stockholders' equity attributable to parent      (0)
Total stockholders' equity:47727263335
TOTAL LIABILITIES AND EQUITY:8153552424947

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues672729271810
Cost of revenue(3)(4)(19)(18)(17)(14)(8)
Gross profit:249111042
Operating expenses(11)(9)(31)(30)(27)(25)(21)
Operating loss:(8)(6)(22)(19)(17)(21)(19)
Nonoperating income (expense)0(2)2(4)100
Investment income, nonoperating004(2)200
Other nonoperating income (expense)00(0)(0)(0)  
Interest and debt expense(0)(0)(2)(0)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(8)(8)(22)(23)(16)(22)(19)
Loss from equity method investments      (1)
Loss from continuing operations before income taxes:(8)(8)(22)(23)(16)(22)(20)
Income tax benefit11 2 12
Loss from continuing operations:(7)(7)(22)(21)(16)(21)(18)
Income from discontinued operations00     
Net loss:(7)(7)(22)(21)(16)(21)(18)
Other undisclosed net income (loss) attributable to parent(1)020001
Net loss attributable to parent:(8)(7)(20)(21)(16)(20)(17)
Other undisclosed net loss available to common stockholders, basic     (0)(0)
Net loss available to common stockholders, diluted:(8)(7)(20)(21)(16)(20)(17)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(7)(7)(22)(21)(16)(21)(18)
Comprehensive loss:(7)(7)(22)(21)(16)(21)(18)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)020   
Comprehensive loss, net of tax, attributable to parent:(8)(7)(20)(21)(16)(21)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: